company background image
HGF2 logo

Catalyst Biosciences DB:HGF2 Stock Report

Last Price

€7.40

Market Cap

€18.3m

7D

25.8%

1Y

-10.6%

Updated

01 Nov, 2023

Data

Company Financials +

Catalyst Biosciences, Inc.

DB:HGF2 Stock Report

Market Cap: €18.3m

HGF2 Stock Overview

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally.

HGF2 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Catalyst Biosciences, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Catalyst Biosciences
Historical stock prices
Current Share PriceUS$7.40
52 Week HighUS$8.88
52 Week LowUS$2.36
Beta1.29
1 Month Change12.13%
3 Month Change63.12%
1 Year Change-10.64%
3 Year Change-89.32%
5 Year Change-94.67%
Change since IPO-99.87%

Recent News & Updates

Recent updates

Shareholder Returns

HGF2DE BiotechsDE Market
7D25.8%1.2%2.5%
1Y-10.6%34.7%7.0%

Return vs Industry: HGF2 exceeded the German Biotechs industry which returned -23.1% over the past year.

Return vs Market: HGF2 underperformed the German Market which returned 5.9% over the past year.

Price Volatility

Is HGF2's price volatile compared to industry and market?
HGF2 volatility
HGF2 Average Weekly Movement22.1%
Biotechs Industry Average Movement5.7%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.1%
10% least volatile stocks in DE Market2.4%

Stable Share Price: HGF2's share price has been volatile over the past 3 months.

Volatility Over Time: HGF2's weekly volatility (22%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
20027Nassim Usmanhttps://www.catalystbiosciences.com

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally. It develops Hydronidone, that has completed phase 1 clinical trial for the treatment of nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease. The company was founded in 2002 and is headquartered in South San Francisco, California.

Catalyst Biosciences, Inc. Fundamentals Summary

How do Catalyst Biosciences's earnings and revenue compare to its market cap?
HGF2 fundamental statistics
Market cap€18.35m
Earnings (TTM)-€41.80m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HGF2 income statement (TTM)
RevenueUS$0
Cost of RevenueUS$1.97m
Gross Profit-US$1.97m
Other ExpensesUS$42.27m
Earnings-US$44.24m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-17.47
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did HGF2 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.